Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16221713rdf:typepubmed:Citationlld:pubmed
pubmed-article:16221713lifeskim:mentionsumls-concept:C0027697lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0064847lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C1334350lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0165796lld:lifeskim
pubmed-article:16221713lifeskim:mentionsumls-concept:C0103512lld:lifeskim
pubmed-article:16221713pubmed:issue12lld:pubmed
pubmed-article:16221713pubmed:dateCreated2005-11-18lld:pubmed
pubmed-article:16221713pubmed:abstractTextONO-4057 is a specific leukotriene B4 (LTB4) receptor antagonist which inhibits human neutrophil aggregation, chemotaxis and degranulation induced by LTB4. This study was conducted to evaluate the role of LTB4 in glomerulonephritis, and to examine whether ONO-4057 moderated anti-Thy-1 nephritis.lld:pubmed
pubmed-article:16221713pubmed:languageenglld:pubmed
pubmed-article:16221713pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:citationSubsetIMlld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16221713pubmed:statusMEDLINElld:pubmed
pubmed-article:16221713pubmed:monthDeclld:pubmed
pubmed-article:16221713pubmed:issn0931-0509lld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:FukudaYutakaYlld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:SuzukiHitoshi...lld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:KawasakiYukih...lld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:NozawaRurikoRlld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:HosoyaMitsuak...lld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:IsomeMasatoMlld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:TanjiMiekoMlld:pubmed
pubmed-article:16221713pubmed:authorpubmed-author:TakanoKeiKlld:pubmed
pubmed-article:16221713pubmed:issnTypePrintlld:pubmed
pubmed-article:16221713pubmed:volume20lld:pubmed
pubmed-article:16221713pubmed:ownerNLMlld:pubmed
pubmed-article:16221713pubmed:authorsCompleteYlld:pubmed
pubmed-article:16221713pubmed:pagination2697-703lld:pubmed
pubmed-article:16221713pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:meshHeadingpubmed-meshheading:16221713...lld:pubmed
pubmed-article:16221713pubmed:year2005lld:pubmed
pubmed-article:16221713pubmed:articleTitleThe leukotriene B4 receptor antagonist ONO-4057 inhibits mesangioproliferative changes in anti-Thy-1 nephritis.lld:pubmed
pubmed-article:16221713pubmed:affiliationDepartment of Pediatrics, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima City, Fukushima 960-1295, Japan. tomo@fmu.ac.jplld:pubmed
pubmed-article:16221713pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16221713pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16221713lld:pubmed